Peter Berglund
About Peter Berglund
Peter Berglund is the CSO with over 25 years of experience in vaccine technology development and evaluation, and is the original inventor of RNA vaccination.
Title: Chief Scientific Officer (CSO)
Peter Berglund serves as the Chief Scientific Officer (CSO). In this role, he oversees scientific strategies, including the development and evaluation of novel vaccine technologies. His responsibilities include guiding research and development projects and maintaining the scientific integrity of research initiatives.
Education and Expertise
Peter Berglund holds a PhD from the prestigious Karolinska Institutet. He has also conducted extensive post-doctoral research at the Karolinska Institutet and the Laboratory of Viral Disease at the National Institutes of Health. His expertise spans over 25 years and includes significant contributions in immune response, memory, and protection against viral infections such as influenza. Berglund is renowned as the original inventor of RNA vaccination.
Professional Background
Peter Berglund has amassed substantial professional experience throughout his career. He previously served as the Executive Director of Research at Immune Design, where he advanced products from discovery through Phase III clinical trials. He also led the vaccine division at Liquidia Technologies and was in charge of vaccine discovery at AlphaVax. Berglund has led teams of dozens and has successfully advanced more than a half-dozen products into clinical trials.
Achievements in Vaccine Technology
Peter Berglund is well-regarded for his pioneering work in vaccine technology. He is the original inventor of RNA vaccination and has played a crucial role in progressing various vaccine products through different phases of clinical trials. At Immune Design, he successfully advanced products from discovery through Phase III clinical trials, exemplifying his proficiency in bringing innovative vaccine solutions to fruition.